Rhythm Pharmaceuticals (RYTM)
NASDAQ:RYTM
Want to see RYTM full AI Analyst Report?
RYTM Stock Chart & Stats
$88.69
-$0.41(-0.68%)
At close: 4:00 PM EST
$88.69
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$60.80 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)753.96K
Market Cap
$6.64B
Enterprise Value$6.74B
Total Cash (Recent Filing)$340.63M
Total Debt (Recent Filing)$227.02M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 04, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding68,593,575
10 Day Avg. Volume980,194
30 Day Avg. Volume753,959
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue31.03
Enterprise Value/Gross Profit34.70
Enterprise Value/Ebitda-37.28
Forecast
1Y Price Target
$137.75Price Target Upside55.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.13
Revenue Forecast (FY)$298.08M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginsSustained top-line growth to $217M TTM paired with ~88–91% gross margins shows attractive unit economics. Durable high gross margins provide structural room to reinvest in launches and R&D while supporting long-term profitability if operating expense growth is controlled.
Regulatory Expansion & Label GrowthNew approvals and positive European opinion materially expand the addressable patient base (U.S. estimate ~10,000 HO patients) and confer first‑mover advantage in a rare disease niche. These durable regulatory wins underpin pricing power, commercial exclusivity, and multi‑market launch optionality.
Commercial Traction And Cash RunwayA >24‑month cash runway alongside early HO launch indicators (150+ start forms, rising reimbursed patients and a scaled U.S. salesforce) supports sustained commercialization and global rollouts. This funding and early adoption create a durable foundation for recurring product revenue.
Bears Say
Persistent Cash Burn & Negative Free Cash FlowConsistent negative operating and free cash flow indicates the business is a real cash consumer, not just an accounting loss. Sustained cash burn forces reliance on external capital, increases dilution risk over time, and constrains the company’s ability to fund unanticipated needs without raising financing.
Elevated Leverage And Shrinking EquityRising debt and materially lower shareholder equity reduce balance‑sheet flexibility. Elevated leverage increases financial risk if revenue growth slows, limits borrowing capacity for opportunistic investments, and places pressure on cash flows to service debt rather than fund growth.
Rising Operating Expenses Delaying ProfitabilityAggressive increases in SG&A and elevated R&D to support launches push up the company’s operating cost base. Even with strong gross margins, persistent high operating spend lengthens the path to operating leverage and makes long‑term profitability more execution‑sensitive.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $60.80 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $6.64B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 43 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on May 05, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.008.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.81.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 68,593,575 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 7.864%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.75 (55.32% Upside)
$137.75 (55.32% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.43%
12-Months-Change
Fundamentals
Return on Equity
-203.25%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
RYTM Company Deck
RYTM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$137.75
▲(55.32% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.82% Insiders
31.22% Mutual Funds
50.73% Other Institutional Investors
1.90% Public Companies and
Individual Investors